GlassScriptPhysician profile
Meredith A Rubado
NPI 1114377413
$538.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $73.82 · 2023: $92.05 · 2024: $25.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrofera LLC | $103.03 | 2021 | |
| Abbvie INC. | $100.06 | 2021-2024 | |
| Abbott Laboratories | $56.41 | 2021-2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $50.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2021-2023 | Farxiga |
| Exact Sciences Corporation | $37.18 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $29.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.50 | 2021 | |
| Glaxosmithkline, LLC. | $14.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.78 | 2021 | |
| Amgen INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Rubado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.